

<b>(51) International Patent Classification<sup>5</sup> :</b> <b>A61K 31/19, 9/00, 47/18</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/15597</b> <b>(43) International Publication Date:</b> 21 July 1994 (21.07.94)
<b>(21) International Application Number:</b> PCT/US94/00188 <b>(22) International Filing Date:</b> 6 January 1994 (06.01.94) <b>(30) Priority Data:</b> 08/003,107                      11 January 1993 (11.01.93)                      US <b>(71) Applicant:</b> ALLERGAN, INC. [US/US]; 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534 (US). <b>(72) Inventor:</b> WONG, Michelle, P.; 15662 Myrtle Avenue, Tustin, CA 92680 (US). <b>(74) Agents:</b> BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> OPTHALMIC COMPOSITIONS COMPRISING BENZYLLAURYLDIMETHYLAMMONIUM CHLORIDE		
<b>(57) Abstract</b>  An ophthalmic solution generally includes an ophthalmologically acceptable drug formulation incompatible with benzalkonium chloride and lauralkonium chloride present in an anti-microbially effective amount. The incompatibility of the ophthalmologically acceptable drug manifests itself by forming insoluble ion pairs with the benzalkonium chloride. It has been found that lauralkonium chloride which is the C <sub>12</sub> homolog of benzalkonium chloride is effective as a preservative without apparent interaction with the acidic ophthalmologically acceptable drug and formulations maintain their antimicrobial efficiency over periods of up to one year or more.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## OPHTHALMIC COMPOSITIONS COMPRISING BENZYL LAURYL DIMETHYLAMMONIUM CHLORIDE

5

The present invention generally relates to improved ophthalmic formulations and solutions and more particularly to improved preservative systems for ophthalmologically acceptable drug formulations which have an incompatibility with benzalkonium chloride. More specifically, the present invention pertains to the preservative for an anti-inflammatory drug such as sodium flurbiprofen (Ocufer®).

10

Ophthalmologically acceptable drug formulations generally contain effective compounds and a number of ophthalmologically acceptable excipients. Such excipients generally include solutions, ointments, and suspensions, etc. More specifically, such excipients include stabilizing agents, surfactants, buffering systems, chelating systems, viscosity agents, and, importantly, a preservative.

15  
20

Ophthalmic formulations, understandably, must be sterile and if a multi-dose regime is intended, the formulation must be preserved with an effective antimicrobial agent.

25

As discussed in U.S. Patent No. 5,110,493, organo-mercurials have been used extensively as the preservatives in ophthalmic solutions. As reported in this reference, these compounds pose difficulties due to potential mercury toxicity as well as poor chemical stability.

Therefore, benzalkonium chloride, which is a quaternary ammonium compound, has been widely used in ophthalmic solutions. It is also well-known, however, that benzalkonium chloride is considered incompatible with anionic drugs, forming insoluble compounds which cause the solution to turn cloudy.

This is because of the fact that many acidic drug entities carry a negative charge at physiological pH. In fact, all acidic drug entities will carry a negative charge at all pH above their pKa.

In the case of benzalkonium chloride, which is a positively charged preservative, ion pairs can be formed with negatively charged drug compounds, forming an insoluble ion pair which causes the drug to precipitate out of solution. Concomitant with the removal of the drug from solution is the removal of benzalkonium chloride, thereby rendering this quaternary germicide incapable of performing its function as an antimicrobial agent.

Benzalkonium chloride is a mixture of alkyldimethylbenzylammonium chloride of the general formula as shown below in which R represents a mixture of the alkyls from  $C_8H_{17}$  to  $C_{18}H_{37}$

As hereinbefore noted, it is well-known that benzalkonium chloride is generally incompatible with anionic detergents or anionic drug compounds.

See U.S. Patent No. 5,110,493, and The Merck Index, 11th Edition, Merck & Co., Inc., 1989.

5           The present invention specifically relates to the discovery that a particular member of a group of compounds, generally known as benzalkonium chloride, exhibits properties totally different from other members of the group and different from the gross properties of the mixture known as benzalkonium chloride.

10           This discovery by the applicant must be taken in the context that all compositions are made of the same substances, retaining their fixed chemical properties. The elements are capable of an infinity of permutations, and selection of that group or element of a group which proves serviceable to a given need requires a high degree of originality.  
15           This general premise relates to the invention at hand. The applicant has discovered that lauralkonium chloride, which is the  $C_{12}$  homolog of benzalkonium chloride, is compatible with acidic drug entities with apparently no insoluble ion pairs being formed therewith. This is contrary to the properties of the mixture of alkyldimethylbenzylammonium chloride,  
20           known as benzalkonium chloride, which includes a mixture of the alkyls from  $C_8H_{17}$  to  $C_{18}H_{37}$ .

#### SUMMARY OF THE INVENTION

25           An ophthalmic solution, in accordance with the present invention, generally includes an ophthalmologically acceptable drug formulation incompatible with benzalkonium chloride and lauralkonium chloride present in an antimicrobially effective amount. More specifically, flurbiprofen is an example of an acidic drug that forms an insoluble ion-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.